Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The study group was 2020 adults.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Randomized, double-blind, parallel-group, 68-week, phase 3a study (STEP 3) conducted at 41 sites in the US from August 2018 to April 2020 in adults without diabetes (N = 611) and with either overweight (body mass index ≥27) plus at least 1 comorbidity or obesity (body mass index ≥30).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Semaglutide.

Some adults received a placebo instead of Semaglutide, giving a reference point.

The Semaglutide group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are Anti-Obesity Agents, Cognitive Behavioral Therapy, Combined Modality Therapy, Diet, Reducing, Glucagon-Like Peptide 1, Glucagon-Like Peptides and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 2020 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (JAMA), a journal based in United States.

More context: the Semaglutide compound page.